Tsuyoshi Inoue

Tsuyoshi Inoue

Auto-generated profile, based on publicly available information

Tsuyoshi Inoue

Department of Physiology of Visceral Function and Body Fluid, Graduate School of Biomedical Sciences, Nagasaki University

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Kidney International
Verified
Journal Article
Open access
KYKentaro Yoshioka
Kentaro Yoshioka
YHYosuke Hirakawa
Yosuke Hirakawa
MKMakoto Kurano
Makoto Kurano
YUYuko Ube
Yuko Ube
YOYoko Ono
Yoko Ono
RIReiko Inagi
Reiko Inagi
Some patients with diabetic kidney disease (DKD) show a fast progression of kidney dysfunction and are known as a "fast decliner" (FD). Therefore, it is critical to understand pathomechanisms specific for fast decline. Here, we performed a comprehensive metabolomic analysis of patients with stage G3 DKD and identified increased urinary lysophosphatidylcholine (LPC) in fast decline. This was confirmed by quantification of urinary LPC using mass spectrometry and identified urinary LPC containing saturated fatty acids palmitic (16:0) and stearic (18:0) acids was increased in FDs. The upsurge in urinary LPC levels was correlated with a decline in estimated glomerular filtration rate after 2.5 years. To clarify a pathogenic role of LPC in FD, we studied an accelerated rat model of DKD and observed an increase in LPC (16:0) and (18:0) levels in the urine and kidney tubulointerstitium as the disease progressed. These findings suggested that local dysregulation of lipid metabolism resulted in excessive accumulation of this LPC species in the kidney. Our in vitro studies also confirmed LPC-mediated lipotoxicity in cultured proximal tubular cells. LPC induced accumulation of lipid droplets via activation of peroxisome proliferator-activated receptor-δ followed by upregulation of the lipid droplet membrane protein perilipin 2 and decreased autophagic flux, thereby inducing organelle stress and subsequent apoptosis. Thus, LPC (16:0) and (18:0) may mediate a fast progression of DKD and may serve as a target for novel therapeutic approaches.

10 April 2014 in Genome Biology
Verified
Journal Article
Open access
PDF file
TITsuyoshi Inoue
Tsuyoshi Inoue
TKTakahide Kohro
Takahide Kohro
TTToshiya Tanaka
Toshiya Tanaka
YKYasuharu Kanki
Yasuharu Kanki
Guoliang LiGuoliang Li
Guoliang Li
YWYouichiro Wada
Youichiro Wada
Background: Synergistic transcriptional activation by different stimuli has been reported along with a diverse array of mechanisms, but the full scope of these mechanisms has yet to be elucidated. Results: We present a detailed investigation of hypoxia-inducible factor (HIF) 1 dependent gene expression in endothelial cells which suggests the importance of crosstalk between the peroxisome proliferator-activated receptor (PPAR) β/δ and HIF signaling axes. A migration assay shows a synergistic interaction between these two stimuli, and we identify angiopoietin-like 4 (ANGPTL4) as a common target gene by using a combination of microarray and ChIP-seq analysis. We profile changes of histone marks at enhancers under hypoxia, PPARβ/δ agonist and dual stimulations and these suggest that the spatial proximity of two response elements is the principal cause of the synergistic transcription induction. A newly developed quantitative chromosome conformation capture assay shows the quantitative change of the frequency of proximity of the two response elements. Conclusions: To the best of our knowledge, this is the first report that two different transcription factors cooperate in transcriptional regulation in a synergistic fashion through conformational change of their common target genes.

1 July 2021 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
SHSho Hasegawa
Sho Hasegawa
TITsuyoshi Inoue
Tsuyoshi Inoue
YNYasuna Nakamura
Yasuna Nakamura
DFDaichi Fukaya
Daichi Fukaya
RURie Uni
Rie Uni
RIReiko Inagi
Reiko Inagi
Significance Statement: The detailed role of neural activity in inflammatory diseases is still unclear because it varies according to the disease situation and responsible cell types. This study shows that activation of β2-adrenergic receptor (Adrb2) signaling in macrophages induces the expression of T cell Ig and mucin domain 3 (Tim3), which contributes to anti-inflammatory phenotypic alterations. Experiments using conditional knockout mice reveal that macrophage Adrb2 signaling directly mitigates LPS-induced systemic inflammation and renal ischemia-reperfusion injury (IRI). The adoptive transfer of Adrb2 signal–activated macrophages also protects against renal IRI, in association with the accumulation of Tim3-expressing macrophages in the renal tissue. These results indicate that macrophage Adrb2 signaling plays critical roles in the severity of AKI. Background: The sympathetic nervous system regulates immune cell dynamics. However, the detailed role of sympathetic signaling in inflammatory diseases is still unclear because it varies according to the disease situation and responsible cell types. This study focused on identifying the functions of sympathetic signaling in macrophages in LPS-induced sepsis and renal ischemia-reperfusion injury (IRI). Methods: We performed RNA sequencing of mouse macrophage cell lines to identify the critical gene that mediates the anti-inflammatory effect of β2-adrenergic receptor (Adrb2) signaling. We also examined the effects of salbutamol (a selective Adrb2 agonist) in LPS-induced systemic inflammation and renal IRI. Macrophage-specific Adrb2 conditional knockout (cKO) mice and the adoptive transfer of salbutamol-treated macrophages were used to assess the involvement of macrophage Adrb2 signaling. Results: In vitro, activation of Adrb2 signaling in macrophages induced the expression of T cell Ig and mucin domain 3 (Tim3), which contributes to anti-inflammatory phenotypic alterations. In vivo, salbutamol administration blocked LPS-induced systemic inflammation and protected against renal IRI; this protection was mitigated in macrophage-specific Adrb2 cKO mice. The adoptive transfer of salbutamol-treated macrophages also protected against renal IRI. Single-cell RNA sequencing revealed that this protection was associated with the accumulation of Tim3-expressing macrophages in the renal tissue. Conclusions: The activation of Adrb2 signaling in macrophages induces anti-inflammatory phenotypic alterations partially via the induction of Tim3 expression, which blocks LPS-induced systemic inflammation and protects against renal IRI.

17 August 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
STShinji Tanaka
Shinji Tanaka
SZShuqiu Zheng
Shuqiu Zheng
YKYugesh Kharel
Yugesh Kharel
RFRussell G. Fritzemeier
Russell G. Fritzemeier
THTao Huang
Tao Huang
MOMark D. Okusa
Mark D. Okusa
Chronic kidney disease (CKD), characterized by sustained inflammation and progressive fibrosis, is highly prevalent and can eventually progress to end-stage kidney disease. However, current treatments to slow CKD progression are limited. Sphingosine 1-phosphate (S1P), a product of sphingolipid catabolism, is a pleiotropic mediator involved in many cellular functions, and drugs targeting S1P signaling have previously been studied particularly for autoimmune diseases. The primary mechanism of most of these drugs is functional antagonism of S1P receptor-1 (S1P1) expressed on lymphocytes and the resultant immunosuppressive effect. Here, we documented the role of local S1P signaling in perivascular cells in the progression of kidney fibrosis using primary kidney perivascular cells and several conditional mouse models. S1P was predominantly produced by sphingosine kinase 2 in kidney perivascular cells and exported via spinster homolog 2 (Spns2). It bound to S1P1 expressed in perivascular cells to enhance production of proinflammatory cytokines/chemokines upon injury, leading to immune cell infiltration and subsequent fibrosis. A small-molecule Spns2 inhibitor blocked S1P transport, resulting in suppression of inflammatory signaling in human and mouse kidney perivascular cells in vitro and amelioration of kidney fibrosis in mice. Our study provides insight into the regulation of inflammation and fibrosis by S1P and demonstrates the potential of Spns2 inhibition as a treatment for CKD and potentially other inflammatory and fibrotic diseases that avoids the adverse events associated with systemic modulation of S1P receptors.

23 June 2023 in Communications Biology
Verified
Journal Article
Open access
PDF file
YNYasuna Nakamura
Yasuna Nakamura
HMHirotaka Matsumoto
Hirotaka Matsumoto
CWChia-Hsien Wu
Chia-Hsien Wu
DFDaichi Fukaya
Daichi Fukaya
RURie Uni
Rie Uni
TITsuyoshi Inoue
Tsuyoshi Inoue
Activation of the cholinergic anti-inflammatory pathway (CAP) via vagus nerve stimulation has been shown to improve acute kidney injury in rodent models. While alpha 7 nicotinic acetylcholine receptor (α7nAChR) positive macrophages are thought to play a crucial role in this pathway, their in vivo significance has not been fully understood. In this study, we used macrophage-specific α7nAChR-deficient mice to confirm the direct activation of α7nAChRs in macrophages. Our findings indicate that the administration of GTS-21, an α7nAChR-specific agonist, protects injured kidneys in wild-type mice but not in macrophage-specific α7nAChR-deficient mice. To investigate the signal changes or cell reconstructions induced by α7nAChR activation in splenocytes, we conducted single-cell RNA-sequencing of the spleen. Ligand-receptor analysis revealed an increase in macrophage-macrophage interactions. Using macrophage-derived cell lines, we demonstrated that GTS-21 increases cell contact, and that the contact between macrophages receiving α7nAChR signals leads to a reduction in TNF-α. Our results suggest that α7nAChR signaling increases macrophage-macrophage interactions in the spleen and has a protective effect on the kidneys.

3 March 2020 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
YHYoshiki Higashijima
Yoshiki Higashijima
YMYusuke Matsui
Yusuke Matsui
TSTeppei Shimamura
Teppei Shimamura
RNRyo Nakaki
Ryo Nakaki
NNNao Nagai
Nao Nagai
YKYasuharu Kanki
Yasuharu Kanki
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.